FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297946293> ?p ?o ?g. }

• W4297946293 endingPage "100589" @default.
• W4297946293 startingPage "100589" @default.
• W4297946293 abstract "5-fluorouracil (5-FU) combined with a folate remains an essential treatment component for metastatic colorectal cancer (mCRC). Leucovorin is the folate most often used, but requires intracellular conversion to a reduced folate, and has high pharmacokinetic variability and limited bioavailability in patients with low folate pathway gene expression. Arfolitixorin is an immediately active form of folate, [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF), and may improve outcomes.This open-label, multicenter, phase I/II study in patients with mCRC (NCT02244632) assessed the tolerability and efficacy of first- or second-line arfolitixorin (30, 60, 120, or 240 mg/m2 intravenous) with 5-FU alone, or in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan, every 14 days. Safety, efficacy, and pharmacokinetics were assessed before and after four cycles (8 weeks) of treatment.In 105 treated patients, investigators reported 583 adverse events (AEs) in 86 patients (81.9%), and 256 AEs (43.9%) were potentially related to arfolitixorin and 5-FU. Dose adjustments were required in 16 patients (15.2%). At 8 weeks, 9 out of 57 patients assessed for efficacy achieved an objective response (15.8%), and all 9 achieved a partial response. Six of these nine patients had received arfolitixorin as a first-line treatment. A further 33 patients (57.9%) achieved stable disease. Pharmacokinetics were assessed in 35 patients. The average tmax was 10 min, and area under the plasma concentration-time curve from time 0 to 1 h increased linearly between 30 and 240 mg/m2. No accumulation was observed for [6R]-MTHF following repeated administration, and there were no major pharmacokinetic differences between cycle 1 and cycle 4 at any dose.Arfolitixorin is a well-tolerated moderator of 5-FU activity. It is suitable for further investigation in mCRC and has the potential to improve treatment outcomes in patients with low folate pathway gene expression. Arfolitixorin can easily be incorporated into current standard of care, requiring minimal changes to chemotherapy regimens." @default.
• W4297946293 created "2022-10-01" @default.
• W4297946293 creator A5013118398 @default.
• W4297946293 creator A5028974841 @default.
• W4297946293 creator A5033071121 @default.
• W4297946293 creator A5035832029 @default.
• W4297946293 creator A5056643910 @default.
• W4297946293 creator A5057702347 @default.
• W4297946293 creator A5063054956 @default.
• W4297946293 creator A5068135845 @default.
• W4297946293 creator A5068848511 @default.
• W4297946293 creator A5071850607 @default.
• W4297946293 creator A5082630114 @default.
• W4297946293 creator A5086594420 @default.
• W4297946293 creator A5087963010 @default.
• W4297946293 date "2022-10-01" @default.
• W4297946293 modified "2023-09-25" @default.
• W4297946293 title "A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer" @default.
• W4297946293 cites W1847455118 @default.
• W4297946293 cites W1870066362 @default.
• W4297946293 cites W1878265365 @default.
• W4297946293 cites W2015445088 @default.
• W4297946293 cites W2019659352 @default.
• W4297946293 cites W2021009641 @default.
• W4297946293 cites W2024506932 @default.
• W4297946293 cites W2024835273 @default.
• W4297946293 cites W2038325346 @default.
• W4297946293 cites W2049266649 @default.
• W4297946293 cites W2060189595 @default.
• W4297946293 cites W2069218108 @default.
• W4297946293 cites W2095317176 @default.
• W4297946293 cites W2103789431 @default.
• W4297946293 cites W2116781863 @default.
• W4297946293 cites W2121368761 @default.
• W4297946293 cites W2123133140 @default.
• W4297946293 cites W2128447158 @default.
• W4297946293 cites W2129255527 @default.
• W4297946293 cites W2135521008 @default.
• W4297946293 cites W2139002359 @default.
• W4297946293 cites W2150985317 @default.
• W4297946293 cites W2162313061 @default.
• W4297946293 cites W2165385913 @default.
• W4297946293 cites W2171232394 @default.
• W4297946293 cites W2274948752 @default.
• W4297946293 cites W2314927739 @default.
• W4297946293 cites W2406010272 @default.
• W4297946293 cites W2408898492 @default.
• W4297946293 cites W2470575266 @default.
• W4297946293 cites W2487599183 @default.
• W4297946293 cites W2712978371 @default.
• W4297946293 cites W2749315192 @default.
• W4297946293 cites W2797024694 @default.
• W4297946293 cites W2891768209 @default.
• W4297946293 cites W2938918172 @default.
• W4297946293 cites W2953093090 @default.
• W4297946293 cites W2954841318 @default.
• W4297946293 cites W2980963825 @default.
• W4297946293 cites W3009139795 @default.
• W4297946293 cites W3009963727 @default.
• W4297946293 cites W3035470988 @default.
• W4297946293 cites W3094350544 @default.
• W4297946293 cites W3130224122 @default.
• W4297946293 doi "https://doi.org/10.1016/j.esmoop.2022.100589" @default.
• W4297946293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36183444" @default.
• W4297946293 hasPublicationYear "2022" @default.
• W4297946293 type Work @default.
• W4297946293 citedByCount "0" @default.
• W4297946293 crossrefType "journal-article" @default.
• W4297946293 hasAuthorship W4297946293A5013118398 @default.
• W4297946293 hasAuthorship W4297946293A5028974841 @default.
• W4297946293 hasAuthorship W4297946293A5033071121 @default.
• W4297946293 hasAuthorship W4297946293A5035832029 @default.
• W4297946293 hasAuthorship W4297946293A5056643910 @default.
• W4297946293 hasAuthorship W4297946293A5057702347 @default.
• W4297946293 hasAuthorship W4297946293A5063054956 @default.
• W4297946293 hasAuthorship W4297946293A5068135845 @default.
• W4297946293 hasAuthorship W4297946293A5068848511 @default.
• W4297946293 hasAuthorship W4297946293A5071850607 @default.
• W4297946293 hasAuthorship W4297946293A5082630114 @default.
• W4297946293 hasAuthorship W4297946293A5086594420 @default.
• W4297946293 hasAuthorship W4297946293A5087963010 @default.
• W4297946293 hasBestOaLocation W42979462931 @default.
• W4297946293 hasConcept C112705442 @default.
• W4297946293 hasConcept C121608353 @default.
• W4297946293 hasConcept C126322002 @default.
• W4297946293 hasConcept C143998085 @default.
• W4297946293 hasConcept C197934379 @default.
• W4297946293 hasConcept C2776694085 @default.
• W4297946293 hasConcept C2777802072 @default.
• W4297946293 hasConcept C2778375690 @default.
• W4297946293 hasConcept C2780259306 @default.
• W4297946293 hasConcept C2780456651 @default.
• W4297946293 hasConcept C2780962732 @default.
• W4297946293 hasConcept C31760486 @default.
• W4297946293 hasConcept C526805850 @default.
• W4297946293 hasConcept C71924100 @default.
• W4297946293 hasConcept C90924648 @default.
• W4297946293 hasConcept C98274493 @default.

• next